Erdanib is identified for this website as a product containing erdafitinib in stated 4 mg and 5 mg strengths. The product-specific manufacturer, marketing authorization holder, dosage form and regulatory status require verification.
Erdafitinib is a small-molecule FGFR tyrosine kinase inhibitor. Its therapeutic role is closely linked to molecular testing because treatment selection for the current U.S. indication depends on identifying susceptible FGFR3 genetic alterations in tumor tissue.
Product identity
| Attribute | Information |
|---|---|
| Product | Erdanib |
| Generic name | Erdafitinib |
| Active ingredient | Erdafitinib |
| Stated strengths | 4 mg and 5 mg |
| Product-specific dosage form | Oral film-coated tablet |
| Drug class | FGFR tyrosine kinase inhibitor |
| Therapeutic category | Antineoplastic |
| Reference product | BALVERSA |
| Original discovery/development | Astex Pharmaceuticals/Janssen collaboration |
| Erdanib manufacturer | Drug International Limited |
What is erdafitinib?
Erdafitinib is an oral targeted anticancer medicine designed to inhibit FGFR signaling. FGFR3 alterations can produce abnormal signaling that contributes to tumor-cell proliferation and survival. Blocking the pathway can interfere with these signals in susceptible tumors.
What does 4 mg or 5 mg mean?
The milligram value describes the quantity of erdafitinib in an individual tablet. Current U.S. BALVERSA labeling identifies 3 mg, 4 mg and 5 mg tablets. The recommended starting regimen is 8 mg once daily, using two 4 mg tablets, with an increase to 9 mg once daily for appropriate patients based on tolerability and serum phosphate monitoring.
The existence of 4 mg and 5 mg tablets does not mean that either strength is independently appropriate as a standard daily dose for every patient.
Erdanib and BALVERSA
BALVERSA is the established reference product for erdafitinib in the major regulatory sources reviewed for this website. The relationship between Erdanib and BALVERSA should not be described as a generic-equivalence relationship unless the relevant regulatory documentation establishes it.
Who developed erdafitinib?
Astex reports that erdafitinib was discovered by Astex and Janssen as part of an exclusive worldwide collaboration and license agreement established in 2008. Janssen subsequently assumed responsibility for clinical development and commercialization.
Why FGFR3 testing matters
Erdafitinib is not a biomarker-independent cancer medicine. Current U.S. labeling requires confirmation of susceptible FGFR3 genetic alterations before treatment.
That makes tumor molecular testing an important part of treatment selection rather than an optional marketing feature.